Paper71400
Polymorphic hydroxylation of Debrisoquine in man.
Mahgoub A and 4 others. Lancet, 1977. Cited by 1,087 papers, by iCite.
Cite this record
ConductScience Library. Polymorphic hydroxylation of Debrisoquine in man. Papers, record 71400. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/71400
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Debrisoquin | Major topic |
| Isoquinolines | Major topic |
| Administration, Oral | |
| Adolescent | |
| Adult | |
| Alleles | |
| Biological Availability | |
| Chemical Phenomena | |
| Chemistry | |
| Child | |
| Female | |
| Genes, Recessive | |
| Genotype | |
| Humans | |
| Hydroxylation | |
| Male | |
| Metabolism, Inborn Errors | |
| Middle Aged |
Source PubMed
Cited by283
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,087 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39054072 | Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism. | Pharmacol Rev | 2024 | https://conductscience.org/library/papers/39054072 | PubMed |
| 38550951 | Maturing pharmacogenomic factors deliver improvements and cost efficiencies. | Camb Prism Precis Med | 2023 | https://conductscience.org/library/papers/38550951 | PubMed |
| 37996916 | Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling. | Hum Genomics | 2023 | https://conductscience.org/library/papers/37996916 | PubMed |
| 37667550 | Design, analysis, and interpretation of treatment response heterogeneity in personalized nutrition and obesity treatment research. | Obes Rev | 2023 | https://conductscience.org/library/papers/37667550 | PubMed |
| 37370844 | Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37370844 | PubMed |
| 36353484 | Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36353484 | PubMed |
| 36015360 | Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36015360 | PubMed |
| 35868640 | Drug Metabolism: A Half-Century Plus of Progress, Continued Needs, and New Opportunities. | Drug Metab Dispos | 2023 | https://conductscience.org/library/papers/35868640 | PubMed |
| 35373152 | From pharmacogenetics to pharmaco-omics: Milestones and future directions. | HGG Adv | 2022 | https://conductscience.org/library/papers/35373152 | PubMed |
| 35123571 | Frequencies of CYP2D6 genetic polymorphisms in Arab populations. | Hum Genomics | 2022 | https://conductscience.org/library/papers/35123571 | PubMed |
| 33424917 | Milestones in Personalized Medicine: From the Ancient Time to Nowadays-the Provocation of COVID-19. | Front Genet | 2020 | https://conductscience.org/library/papers/33424917 | PubMed |
| 33363564 | How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? | Front Genet | 2020 | https://conductscience.org/library/papers/33363564 | PubMed |
| 33143137 | A Review of the Important Role of CYP2D6 in Pharmacogenomics. | Genes (Basel) | 2020 | https://conductscience.org/library/papers/33143137 | PubMed |
| 32916938 | Precision Medicine: Steps along the Road to Combat Human Cancer. | Cells | 2020 | https://conductscience.org/library/papers/32916938 | PubMed |
| 32848197 | Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists. | Pharmacogenomics J | 2021 | https://conductscience.org/library/papers/32848197 | PubMed |
| 32837681 | A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. | Toxicol Res | 2021 | https://conductscience.org/library/papers/32837681 | PubMed |
| 31648367 | Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses. | Br J Pharmacol | 2020 | https://conductscience.org/library/papers/31648367 | PubMed |
| 31544239 | PharmVar GeneFocus: CYP2D6. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/31544239 | PubMed |
| 31283429 | Gene-Based Dose Optimization in Children. | Annu Rev Pharmacol Toxicol | 2020 | https://conductscience.org/library/papers/31283429 | PubMed |
| 30677473 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. | Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30677473 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/71400
GET https://conductscience.org/api/papers/v1/71400/cited_by?page=2